Skip to content

Schrodinger SDGR Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$427.67M-4.1%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$664.33M+386%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$151.57M+61.3%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$58.6M-1.6%
Gross profit$29.5M-5.1%
Operating income-$48.8M+4.1%
Net income-$60.0M-0.4%
EPS (diluted)-$0.81+1.2%

Balance sheet

See full
Cash & equivalents$267.7M-20.7%
Total debt$107.0M-7.9%
Total equity$313.5M-16.1%
Total assets$634.2M-14.6%

Cash flow

See full
Operating cash flow-$14.8M-110%
CapEx$2.5M+321%
Free cash flow-$17.3M-112%

Valuation

See full
Market cap$1.21B-19.7%
Enterprise value$1.05B-18.3%
P/S4.7×-1.8×

Profitability

See full
Gross margin55.3%-7.3pp
Operating margin-64.7%-12.0pp
Net margin-68.5%
FCF margin9.6%+5.1pp

Returns & leverage

See full
Return on equity-45.7%
Debt / equity0.3×0.0×
Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's cash, cash equivalents, and marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schrodinger's cash, cash equivalents, and marketable securities?
Schrodinger (SDGR) reported cash, cash equivalents, and marketable securities of $138.7M in Q1 2026.
What does cash, cash equivalents, and marketable securities mean?
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.